New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors

We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.

This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.

The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.

Latest In Research


Entrectinib approved for ROS1 and NTRK

From FDA Approves Entrectinib for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors Entrectinib approval Genentech, a member of the Roche Group, today announced…


Liquid Biopsy: Are We Ready for a ‘Blood-First’ Approach?

From: IASLC Lung Cancer News Although the discovery of liquid biopsy testing looks to be a promising, non-invasive test to determine a patient's biomarkers, it hasn't been adopted into the mainstream quite yet. Targeted therapy has …


Long-Term Survival for EGFR+

From Targeted Oncology Sequential afatinib (Gilotrif) followed by osimertinib (Tagrisso) has demonstrated a long-term overall survival (OS) of close to 4 years in patients with non–small cell lung cancer (NSCLC) who have EGFR&nbs…


Blood Test Could Identify Potential Lung Cancer Markers

From Massachusetts General Hospital Blood test to ID lung cancer By examining both blood samples and tumor tissues from patients with non-small-cell lung cancer (NSCLC), investigators at Massachusetts General Hospital (MGH) have iden…


Clinical Trial Navigators

From The New York Times Fewer than 5 percent of cancer patients participate in research that could improve care. Clinical Trial Navigators could help patients find the right studies. Since a Phase I trial has prolonged my life for al…


FDA approves Keytruda for SCLC

FDA approves Keytruda The FDA approved pembrolizumab monotherapy for patients with metastatic small cell lung cancer that progressed on or after platinum-based chemotherapy and at least one other prior line of therapy. This marks…


The Relationship Between Air Pollution and Lung Cancer in Nonsmokers

From Science Direct Relationship between air pollution and lung cancer in nonsmokers - is there one? For never-smokers (smoked <100 lifetime cigarettes), lung cancer  has emerged as an important issue. We aimed to investigate the …


What good is it to be able to cure cancer if we routinely fail to deliver that cure?

From MedScape 'How Could We Fail so Miserably?' Real-World Evidence Offers Sobering Reality We are doing an unconscionably poor job of delivering appropriate targeted therapies to our patients. That's the only conclusion I can draw, bas…


Artificial intelligence and cancer

From Fred Hutch News Service New study tests ability of natural language processing to search lung cancer patients’ records for treatable mutations When rural Minnesota music teacher Shelly Engfer-Triebenbach started getting winded while…


Know Your Genes: Testing for Genomic Mutations in Lung Cancer

From Cure Today Testing for genomic mutations in lung cancer helps pinpoint targeted therapies. Amanda Nerstad was 39 years old and a busy working mother of two young children when she learned she had metastatic lung cancer in 2016. She was…

Read More